Renalytix Plc – NASDAQ:RNLX

Financial Health
0
1
2
3
4
5
6
7
8
9

Renalytix stock price monthly change

-24.11%
month

Renalytix stock price quarterly change

-55.46%
quarter

Renalytix stock price yearly change

-83.69%
year

Renalytix key metrics

Market Cap
22.54M
Enterprise value
71.73M
P/E
-1.47
EV/Sales
26.04
EV/EBITDA
-1.56
Price/Sales
33.27
Price/Book
3.62
PEG ratio
0.01
EPS
-1.14
Revenue
2.60M
EBITDA
-33.69M
Income
-47.56M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-1760.64%
Oper. margin
-1862.71%
Gross margin
21.13%
EBIT margin
-1862.71%
EBITDA margin
-1291.79%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Renalytix stock price history

Renalytix stock forecast

Renalytix financial statements

Renalytix Plc (NASDAQ:RNLX): Profit margin
Jun 2022 831K -16.60M -1998.68%
Mar 2023 724K -12.10M -1672.1%
Jun 2023 518K -11.10M -2143.63%
Mar 2024 535K -7.74M -1447.29%
Renalytix Plc (NASDAQ:RNLX): Analyst Estimates
2026 50.42M -14.32M -28.4%
2027 114.3M 19.73M 17.26%
  • Analysts Price target

  • Financials & Ratios estimates

Renalytix Plc (NASDAQ:RNLX): Debt to assets
Dec 2022 30660000 21.77M 71.02%
Mar 2023 39802000 21.70M 54.53%
Jun 2023 30629000 23.66M 77.25%
Mar 2024 8769000 19.88M 226.71%
Renalytix Plc (NASDAQ:RNLX): Cash Flow
Jun 2022 -13.98M 28K 25.19M
Mar 2023 -10.10M 5K 18.01M
Jun 2023 -8.63M 59K -98K
Mar 2024 -4.86M -3K 4.03M

Renalytix alternative data

Renalytix Plc (NASDAQ:RNLX): Employee count
Aug 2023 102
Sep 2023 102
Oct 2023 102
Nov 2023 102
Dec 2023 102
Jan 2024 102
Feb 2024 102
Mar 2024 102
Apr 2024 102
May 2024 102
Jun 2024 102
Jul 2024 102

Renalytix other data

1.82% -2.81%
of RNLX is owned by hedge funds
1.36M -2.09M
shares is hold by hedge funds
Insider Compensation
Mr. James R. McCullough M.B.A. (1968) Chief Executive Officer & Executive Director
$1,130,000
Mr. Fergus Fleming (1967) Chief Technology Officer & Executive Director
$587,000
Thursday, 11 July 2024
globenewswire.com
Thursday, 27 June 2024
globenewswire.com
Friday, 14 June 2024
globenewswire.com
Wednesday, 15 May 2024
seekingalpha.com
globenewswire.com
Thursday, 9 May 2024
GlobeNewsWire
Monday, 25 March 2024
InvestorPlace
Thursday, 15 February 2024
Proactive Investors
Friday, 9 February 2024
Proactive Investors
Thursday, 26 October 2023
Zacks Investment Research
Monday, 16 October 2023
Zacks Investment Research
Thursday, 12 October 2023
Zacks Investment Research
Friday, 6 October 2023
Proactive Investors
Thursday, 5 October 2023
Zacks Investment Research
Tuesday, 3 October 2023
Proactive Investors
Friday, 29 September 2023
Seeking Alpha
Monday, 25 September 2023
GlobeNewsWire
Friday, 21 July 2023
Proactive Investors
Sunday, 16 July 2023
Seeking Alpha
Friday, 30 June 2023
InvestorPlace
Thursday, 30 March 2023
Seeking Alpha
Wednesday, 22 March 2023
GlobeNewsWire
Wednesday, 1 March 2023
Seeking Alpha
Wednesday, 30 November 2022
Seeking Alpha
Thursday, 3 November 2022
GlobeNewsWire
Monday, 31 October 2022
Seeking Alpha
Thursday, 8 September 2022
GlobeNewsWire
Monday, 25 July 2022
Seeking Alpha
Thursday, 30 June 2022
Seeking Alpha
Thursday, 23 June 2022
GlobeNewsWire
  • When is Renalytix's next earnings date?

    Unfortunately, Renalytix's (RNLX) next earnings date is currently unknown.

  • Does Renalytix pay dividends?

    No, Renalytix does not pay dividends.

  • How much money does Renalytix make?

    Renalytix has a market capitalization of 22.54M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 32.74% to 2.29M US dollars.

  • What is Renalytix's stock symbol?

    Renalytix Plc is traded on the NASDAQ under the ticker symbol "RNLX".

  • What is Renalytix's primary industry?

    Company operates in the Healthcare sector and Medical - Healthcare Information Services industry.

  • How do i buy shares of Renalytix?

    Shares of Renalytix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Renalytix's key executives?

    Renalytix's management team includes the following people:

    • Mr. James R. McCullough M.B.A. Chief Executive Officer & Executive Director(age: 57, pay: $1,130,000)
    • Mr. Fergus Fleming Chief Technology Officer & Executive Director(age: 58, pay: $587,000)
  • How many employees does Renalytix have?

    As Jul 2024, Renalytix employs 102 workers.

  • When Renalytix went public?

    Renalytix Plc is publicly traded company for more then 5 years since IPO on 17 Jul 2020.

  • What is Renalytix's official website?

    The official website for Renalytix is renalytix.com.

  • Where are Renalytix's headquarters?

    Renalytix is headquartered at 1460 Broadway, New York, NY.

  • How can i contact Renalytix?

    Renalytix's mailing address is 1460 Broadway, New York, NY and company can be reached via phone at +64 6 397 3970.

Renalytix company profile:

Renalytix Plc

renalytix.com
Exchange:

NASDAQ

Full time employees:

102

Industry:

Medical - Healthcare Information Services

Sector:

Healthcare

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

1460 Broadway
New York, NY 10036

CIK: 0001811115
ISIN: US75973T1016
CUSIP: 75973T101